Active, not recruitingPhase 2NCT05142241

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Studying Hereditary pheochromocytoma-paraganglioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
A P Chen
National Cancer Institute LAO
Intervention
Biopsy Procedure(procedure)
Enrollment
14 enrolled
Eligibility
12 years · All sexes
Timeline
20222026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05142241 on ClinicalTrials.gov

Other trials for Hereditary pheochromocytoma-paraganglioma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary pheochromocytoma-paraganglioma

← Back to all trials